In a Japanese cohort study, low serum IL-33 levels, low peak expiratory flow variability over 1 week, childhood onset of asthma (at age <10 years), and high serum IL-10 levels were associated with a safe reduction in ICS dose. The gene discussed is IL33; the disease is asthma.